NCT06310642 (PAMS) is a Phase 4 clinical trial of Immediate descent from altitude. in AMS, sponsored by CHRISTUS Health.

Who is sponsoring NCT06310642?

NCT06310642 is sponsored by CHRISTUS Health.

What drugs are being tested in NCT06310642?

Interventions in NCT06310642: Immediate descent from altitude., Diphenhydramine, Prochlorperazine 10 mg.

What condition does NCT06310642 study?

NCT06310642 studies AMS, Acute Mountain Sickness.

Is NCT06310642 still recruiting?

NCT06310642 is currently completed. Last updated 28 May 2024.

Last reviewed 2024-05-28 · How we verify

NCT06310642: PAMS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Prophylactic Treatment of Oral Prochlorperazine for Acute Mountain Sickness

Completed Phase 4 Last updated 28 May 2024

What this trial tests

Phase 4 trial testing Immediate descent from altitude. in AMS in 30 participants. Completed in 13 March 2023.

Timeline

20 May 2021

Primary endpoint
13 March 2023

13 March 2023

Quick facts

Lead sponsor	CHRISTUS Health
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	30
Start date	20 May 2021
Primary completion	13 March 2023
Estimated completion	13 March 2023
Sites	1 location across United States

Drugs / interventions tested

Immediate descent from altitude.
Diphenhydramine (diphenhydramine) — full drug profile →
Prochlorperazine 10 mg — full drug profile →

Conditions studied

AMS — all drugs for AMS →
Acute Mountain Sickness — all drugs for Acute Mountain Sickness →

Sponsor

CHRISTUS Health — full company profile →

Who can join

18 and older, any sex, with AMS or Acute Mountain Sickness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A field-based trial was conducted to determine if oral prochlorperazine demonstrates efficacy in the prophylactic treatment of AMS, and/or decreases the incidence of the symptoms of acute mountain sickness including headache, GI symptoms, fatigue and dizziness based on data collected in the Lake Louise AMS score.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other CHRISTUS Health trials

Trials by the same sponsor.

NCT06726811 — Droperidol and QTc Interval Changes in ED Patients · recruiting
NCT06555315 — Pilot Trial Investigating Every Other Day Dosing of Oral Iron in Premature Infants (IQONic) · NA · recruiting
NCT06589284 — Skin Glue Versus Suture for Securing Radial Arterial Lines · NA · completed
NCT04869579 — Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients. · Phase 2 · unknown
NCT06059417 — Foam Tape Allergy a Sticky Situation · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06310642 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CHRISTUS Health
Last refreshed: 28 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06310642.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing